ATHA: צמיחת הכנסות רבעונית Athira Pharma, Inc.

Athira Pharma, Inc. (ATHA) is currently pivoting its strategy to focus on rare brain pathologies following setbacks with its lead drug candidate. Current quarterly revenue growth reflects the market reaction, where the latest parameter stands at 0.00. Development is being conducted in Washington with the involvement of external synthesis partners. The company plans to generate revenue from insurance reimbursements for innovative therapies targeting dementia and Alzheimer's disease.
פילוחי נתונים אנליטיים מרוכזים עבור Athira (ATHA)

This indicator measures the dynamics of quarterly inflows relative to previous periods, allowing investors to assess the pace of business expansion or stagnation through changes in quarterly revenue. For Athira Pharma, Inc. (ATHA), this metric is critical, as restructuring following failures in Alzheimer's therapy and a liquidity deficit make any revenue growth the primary marker of the company's viability against the risks of early-phase research.